DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidMLAMSRAGP

Non-specific low back pain and inflammatory back-pain red flags

Essential points for quick revision.

!
Possible cauda equina syndrome

New urinary retention or impaired urinary-flow sensation, saddle sensory change, bilateral sciatica, progressive leg weakness, reduced anal tone or new faecal incontinence can reflect compressive cauda equina syndrome.

Action: Arrange immediate emergency spinal assessment and MRI through the local pathway, document bladder, saddle, motor and sensory findings and onset time, and never wait for outpatient treatment or progression.

Synopsis

Classify low back pain safely, exclude neurological, malignant, infectious, fracture and vascular emergencies, recognise inflammatory patterns, avoid low-value imaging and medicines, and support active recovery through staged biopsychosocial care.

  • Screen every new or changed episode for cauda equina, progressive motor loss, infection, cancer, fracture and vascular or visceral causes before calling it non-specific.
  • Do not routinely image non-specific low back pain in non-specialist care; incidental degeneration is common and imaging is useful only when it changes management.
  • Advise continued ordinary activity, self-management and return to work where feasible; prolonged bed rest weakens muscle and reinforces fear.

Key red flags

New bladder dysfunction, saddle sensory change, bilateral neurological symptoms or progressive motor deficit requires immediate cauda-equina or spinal compression assessment.

Investigation priorities

01
First-line clinical triageFirst stepFirst line

Classify non-specific, radicular, inflammatory and dangerous patterns and choose emergency care or active conservative management.

Management branches

First-line non-specific careKeep recovery active

Assessment finds no serious cause, progressive neurological loss or compelling inflammatory referral pattern.

  1. Explain favourable natural history, advise normal activity and early work participation within tolerance, and provide return advice for bladder, saddle, weakness, fever, trauma or deterioration.
  2. Use risk stratification at first contact to match simple self-management to low-risk episodes and intensive physical or psychological support to likely poor recovery.

Key medicines

Naproxen with gastroprotectionUse 250–500 mg orally twice daily with food for the shortest acute course; when gastrointestinal risk warrants, add omeprazole 20 mg orally once daily for the duration.
Codeine phosphate for exceptional acute useUse 30–60 mg orally every four hours when required for only a few days, never exceeding 240 mg in 24 hours, solely when an NSAID is unsuitable; set a stop date.
Open full textbook Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom